THE PROGNOSTIC EFFECT OF GENES IN THE P53 PATHWAY IN CHRONIC LYMPHOCYTIC LEUKEMIA

Abstract

Chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western world, characterized by the accumulation of small, non-dividing B lymphocytes in various lymphoid tissues, bone marrow and blood. The disease prognosis is heterogenous. Clinical staging methods (Rai and Binet) are used to make individual therapeutic decisions in patients and to predict prognosis and tumor burden. The prognosis of patients with CLL during diagnosis is important in terms of long-term survival and remission of patients. Therefore, apart from classical staging methods, it is necessary to develop prognostic parameters that can predict the course of the disease genetically without predicting the prognosis of the disease. The determination of differences in gene expressions in CLL cases is effective in their use as molecular markers.